Division of Endocrinology, Boston Children's Hospital, Boston, Massachusetts.
Division of Pediatric Endocrinology, Benioff Children's Hospital, University of California at San Francisco, San Francisco, California.
J Adolesc Health. 2020 Sep;67(3):376-383. doi: 10.1016/j.jadohealth.2020.03.028. Epub 2020 May 14.
The purpose of this study was to describe baseline physical and laboratory characteristics of participants in the largest prospective study of transgender and gender-diverse (TGD) youth in the United States.
Participants were recruited from four clinics which specialize in the care of TGD youth before starting either GnRH analogs for pubertal suppression or gender-affirming hormone treatment. Anthropometric and laboratory measurements were abstracted from the medical chart. Baseline characteristics including height, weight, body mass index, blood pressure, and laboratory measurements were compared with those of age-matched National Health and Nutritional Examination Survey comparison group.
Seventy-eight TGD youth with a median age of 11 years (range 8-14 years) were recruited before pubertal suppression, of whom 41 (53%) were designated male at birth, and 296 participants with a median age of 16 years (range 12-20 years) were recruited before beginning gender-affirming hormones, of whom 99 (33%) were designated male at birth. The mean high-density lipoprotein cholesterol was lower in the study participants when compared with that of National Health and Nutritional Examination Survey participants (50.6 ± 12.3 mg/dL vs. 53.3 ± 13.3 mg/dL, p = .001). Otherwise, the study cohorts were similar in terms of body mass index, proportion of overweight and obesity, blood pressure, and baseline laboratory variables.
Before starting gender-affirming treatment, TGD youth are physiologically similar to the general population of children and adolescents in the United States, with the exception of slightly lower high-density lipoprotein cholesterol. Evaluation of this cohort over time will define the physiological effects of pubertal blockade and gender-affirming hormone treatment.
本研究旨在描述美国最大的跨性别和性别多样化（TGD）青年前瞻性研究参与者的基线身体和实验室特征。
参与者从四家专门为 TGD 青年提供护理的诊所招募，这些诊所的青年在开始使用 GnRH 类似物进行青春期抑制或性别肯定激素治疗之前。从病历中提取人体测量学和实验室测量值。将基线特征（包括身高、体重、体重指数、血压和实验室测量值）与年龄匹配的国家健康和营养检查调查（NHANES）对照组进行比较。
在开始青春期抑制之前，招募了 78 名中位年龄为 11 岁（范围 8-14 岁）的 TGD 青年，其中 41 名（53%）出生时被指定为男性，在开始性别肯定激素治疗之前，招募了 296 名中位年龄为 16 岁（范围 12-20 岁）的参与者，其中 99 名（33%）出生时被指定为男性。与 NHANES 参与者相比，研究参与者的高密度脂蛋白胆固醇平均值较低（50.6 ± 12.3mg/dL 与 53.3 ± 13.3mg/dL，p =.001）。否则，研究队列在体重指数、超重和肥胖比例、血压和基线实验室变量方面与一般人群相似。
在开始性别肯定治疗之前，TGD 青年在生理上与美国一般儿童和青少年人群相似，除了高密度脂蛋白胆固醇略低。随着时间的推移对该队列进行评估将确定青春期阻滞和性别肯定激素治疗的生理影响。
